Screener
Harrow HROW Compounding — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | Branded | Compounding | Consolidated |
|---|---|---|---|
| Gross profit | 19,750,000 | 7,295,000 | 27,045,000 |
| Operating expenses | |||
| Selling, general and administrative | 25,759,000 | 6,742,000 | 32,501,000 |
| Research and development | 5,621,000 | 210,000 | 5,831,000 |
| Segment contribution | $(11,630,000) | $343,000 | (11,287,000) |
| Corporate | - | - | 10,729,000 |
| Research and development | 64,000 | ||
| Loss from operations | $(22,080,000) |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's compounding — research and development expense?
- Harrow (HROW) reported compounding — research and development expense of $210K in Q1 2026.
- How has Harrow's compounding — research and development expense changed year-over-year?
- Harrow's compounding — research and development expense decreased by 6.3% year-over-year, from $224K to $210K.
- What does compounding — research and development expense mean?
- This metric tracks the expenditures dedicated to the discovery, formulation, and clinical evaluation of new or improved compounded ophthalmic products. It represents the company's commitment to innovation and long-term product pipeline development within the compounding segment. High levels of investment here are typically indicative of a strategy focused on future market expansion and competitive differentiation.
Ask your AI about Harrow's compounding — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude